Biostar Asia have attended the Hong Kong & Guangzhou International Conference on Stem Cell & Regenerative Medicine 2017

Hong Kong, 16 November 2017 – Hong Kong Science and Technology Parks Corporation (“HKSTP”) and Guangzhou Institutes of Biomedicine and Health (“GIBH”) co-hosted the third Hong Kong and Guangzhou International Conference on Stem Cell and Regenerative Medicine, held at Hong Kong Science Park on 9 November. The event was attended by high-profile guests, including Mr Nicholas Yang, Secretary for Innovation and Technology of the HKSAR Government, and Mr Cao Jinghua, Director General, Bureau of International Cooperation, Chinese Academy of Sciences (CAS).

 

The conference was staged as HKSTP and GIBH developed closer links after GIBH announced in last year’s conference the establishment of the GIBH’s Hong Kong Centre at Hong Kong Science Park. In July this year, the Centre opened the demonstration and exhibition unit and R&D office of its stem cell and regenerative medicine research centre to drive biomedical technology development and catalyse the interaction and collaboration among industry experts and the academia in related areas.

 

Opening the conference, HKSTP Chief Executive Officer Mr Albert Wong pointed to the strong emphasis that both Mainland China and Hong Kong are putting on innovation and technology and the immense opportunities for Hong Kong as the bridge between China and the rest of the world, given Hong Kong’s integral role in China’s plan of fostering the Greater Bay Area into a global innovation centre, and in facilitating China’s economic integration with the world and building the Belt and Road.
“We have one of the best medical systems in the world, a comprehensive Chinese clinical data record, two clinical trial centres that are accredited internationally, including the CFDA, an English-speaking environment, rule of law and freedom of information. We also have renowned clinicians and scientists who are well-connected to the global research community,” he said. “With an ageing population and an expanding middle-class in China, the demand for medical and health services is growing rapidly. Hong Kong is well-positioned to be a research and translational hub for advanced therapies targeted at the Chinese population and a gateway to the China market.”

 

The China-Hong Kong synergy was also underscored by Mr Cao of CAS, who highlighted the significance that both Mainland China Government and the HKSAR Government attach to stem cell and regenerative medicine. “China is the best for science innovation nowadays.

 

The Hong Kong region is excellent for science innovation. Jointly, we make a bigger difference,” he said. “Stem cell and regenerative medicine is one of the fastest growing fields in modern biological science. Mainland China and Hong Kong attach much importance to this very exciting and promising field. With the inauguration of the GIBH Hong Kong centre at Hong Kong Science Park, I am sure the partnership with Hong Kong will not only flourish but also scale new heights in making contributions to global health.”

 
Recent Posts